Fig. 4
From: Alemtuzumab for multiple sclerosis: the new concept of immunomodulation
Time-course repopulation of lymphocyte subpopulations in alemtuzumab-treated multiple sclerosis patients
Fig. 4 | Multiple Sclerosis and Demyelinating Disorders